期刊文献+

老年卵巢癌术后腹腔热灌注化疗的毒副作用分析 被引量:13

Toxic and Side Effects of Intraperitoneal Hyperthermic Perfusion Chemotherapy on Advanced Ovarian Cancer Postoperatives
下载PDF
导出
摘要 目的探讨腹腔热灌注化疗联合全身静脉化疗在老年上皮性卵巢癌术后辅助治疗的毒副作用。方法 25例老年上皮性卵巢癌患者,分别采用腹腔热灌注化疗+全身静脉化疗(IP组)和单纯全身静脉化疗(IV组),比较两组治疗后的毒副作用。结果两组恶心、呕吐的程度比较,差异有统计学意义(P=0.036);两组血液学毒性、肝肾功能损害、周围神经毒性、腹痛、心脏毒性和发热的程度比较,差异均无统计学意义(P>0.05)。结论腹腔热灌注化疗联合全身静脉化疗作为Ⅱ期以上的老年上皮性卵巢癌术后的一种辅助治疗方法,未增加毒副作用,耐受性好。 Objective To explore the toxic and side effects of treating epithelial ovarian cancer with intraperitoneal hyperthermic chemotherapy(IPHC) plus intravenous chemotherapy after cytoreductive surgery.Methods 25 patients with advanced epithelial ovarian cancer were randomly assigned to receive a combination of IPHC plus venous chemotherapy(IP group) and pure venous chemotherapy(IV group).We made a comparison between the two groups about the toxic and side effects arising from the respective treatments.Results There was a statistically significant difference between the two groups in terms of nausea severity and vomiting degree(P=0.036),while no significance could be found in hematological toxicity,liver dysfunction injury,peripheral neurotoxicity,bellyache,cardiac toxicity and fevering degree(P0.05).Conclusion The combination of IPHC plus venous chemotherapy is an auxiliary treatment method for advanced epithelial ovarian carcinoma above Ⅱ phase after cytoreductive surgery with the advantages of little toxic and side effects and good toleration of the patients.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第5期565-567,共3页 Chinese General Practice
关键词 卵巢肿瘤 腹腔热灌注 抗肿瘤联合化疗方案 毒副作用 Ovarian neoplasms Intraperitoneal hyperthermic Antineoplastic combined chemotherapy protocols Toxic and side effect
  • 相关文献

参考文献15

  • 1陈东东,陈桂莲,张秀萍.卵巢癌辅助化疗的研究进展[J].中国全科医学,2011,14(20):2347-2349. 被引量:11
  • 2Muggia FM,Braly PS,Brady MF,et al.Phase Ⅲ randomized study of cisplatin versus pacli-taxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer:A Gynecologic Oncology Group study[J].J Clin Oncol,2000,18:106-115.
  • 3Ozols RF,Bundy BN,Greer BE,et al.Gynecologic Oncology Group.Phase Ⅲ trial of carbo-platin and paclitaxel compared with cisplatin andpaclitaxel in patients with optimally resected stage Ⅲ ovarian cancer:A Gynecologic Oncology Group study[J].J Clin Oncol,2003,21:3194 -3200.
  • 4Alberts DS,Green S,Hannigan EV,et al.Improved therapeutic index of carboplatin plus cyclo-phosphamide versus cisplatin plus cyclophosphamide:final report by the Southwest Oncology Group of a phase Ⅲ randomized trial in stages Ⅲ and Ⅳ ovarian cancer[J].J Clin Oncol,1992,10:706-717.
  • 5张元莉,王权,王灿,何曦冉,王世言,关泉林.进展期胃癌术后早期腹腔灌注化疗对患者生存期和复发率影响的Meta分析[J].中国全科医学,2011,14(30):3487-3490. 被引量:6
  • 6Gadducci A,Conte PF.Intraperitoneal chemotherapy in the management of patients with ad-vanced epithelial ovarian cancer:a critical review of the literature[J].Int J Gynecol Cancer,2008,18:943-953.
  • 7Elit L,Oliver TK,Covens A,et al.Intraperitoneal chemotherapy in the first-line treatment of women with stage Ⅲ epithelial ovarian cancer:a systematic review with metaanalyses[J].Cancer,2007,109:692-702.
  • 8Hess LM,Benham-Hutchins M,Herzog TJ,et al.A meta-analysis of the efficacy of intra-peritoneal cisplatin for the front-line treatment of ovarian cancer[J].Int J Gynecol Cancer,2007,17:561-570.
  • 9Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].N Engl J Med,2006,354:34-43.
  • 10赵宏亚,王明训.大肠癌手术后一次性动脉灌注及腹腔温热化疗的临床研究[J].中国基层医药,2009,16(10):1807-1808. 被引量:5

二级参考文献64

共引文献41

同被引文献112

  • 1韦佩佳.老年复发卵巢癌患者预后影响因素[J].中国老年学杂志,2014,34(8):2081-2082. 被引量:10
  • 2崔书中.腹腔热灌注化疗在胃癌治疗中的应用新进展[J].消化肿瘤杂志(电子版),2012,4(4):211-216. 被引量:8
  • 3牛建昭,魏育林,艾浩,薛晓鸥.临床化疗对卵巢功能的影响[J].中日友好医院学报,2006,20(3):181-183. 被引量:9
  • 4Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and impli- cations for its use in clinical screening [ J ] . Gynecol Oncol, 2003, 88 (1): 152-157.
  • 5Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperther- mic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer [J ] . J Surg Oncol, 2010, 101 (2): 149-155.
  • 6Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer [ J ] . Gynecol Oncol, 2004, 94 (2): 325-332.
  • 7Bayon LG, Steiner MA, Jimenez WV, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at .9 rst recurrence, or later? [J ] . Ejso - Eur JSurg Oncol, 2013 ; in press, Available : http : // www. eia. doe.
  • 8gov Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epi- thelial ovarian cancer: benefits on survival for patients with residual disease of O. 1 - 1 cm after secondary cytoreduction [J ] . Surg Oncol, 2010, 101 (3) : 244-250.
  • 9黄耀球,王凯.卵巢癌腹腔热灌注化疗中的应用及护理[A].中华护理学会.“全国护理管理改革创新”高层论坛、全国护理新理论、新方法、新技术研讨会论文汇编[C].中华护理学会,2011:3.
  • 10Tentes AA,Kakolyris S,Kyziridis D,et al.Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer[J].J Oncol,2012,2012:358341.

引证文献13

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部